According to the Zhitong Finance App, Kingsley Biotech (01548) released its 2017 annual results. Earnings increased 33% year over year to US$152.6 million; gross profit increased 37.3% year over year to US$104.6 million; profit attributable to shareholders decreased 0.4% year over year to US$26.1 million; adjusted net profit (after deducting loss of investment income, loss of foreign currency exchange earnings and share-based payment expenses) increased 52% year over year to US$34.8 million; earnings per share increased 52% year over year; earnings per share were 1.52 cents.

During the reporting period, the company's three major divisions generated revenue of about US$122.5 million for bioscience services and products, US$11.8 million for industrial synthetic biological products, and US$18.3 million for cell therapy, respectively, accounting for about 80.3%, 7.7% and 12.0% of total revenue, respectively.

According to the announcement, the increase in revenue and gross profit was mainly due to continuous R&D activities that enabled the company to launch advanced and better services and products, and increased production competitiveness, which led to a sharp rise in the number of orders for bioscience services and products and novel antibody drugs and biosimilar development services; the increase in customers and purchases of industrial synthetic biological products, mainly due to the upgrading of the product and configuration sales team; and cooperation with Janssen.

Looking ahead to 2018, the Group will further invest in R&D and production capacity to further improve the quality of the sales and marketing team, thereby continuing to increase the company's market share in the following fields, and complement and enhance internal growth through strategic acquisition of advanced technology and technology with a valuable link to the company's business through the strategic acquisition of advanced technology and technology with existing performance that is invaluable to the company's business.